Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 19/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8202554 | 0.90 | CACNA1H (0.85) | CACNA1H | |
| SCHEMBL8201883 | 0.88 | CACNA1H (0.81) | CACNA1H | |
| SCHEMBL8202132 | 0.87 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8205337 | 0.85 | CACNA1H (0.77) | CACNA1H | |
| SCHEMBL8210092 | 0.83 | CACNA1H (0.74) | CACNA1HCYP3A4 | |
| SCHEMBL12876303 | 0.82 | CACNA1H (0.70) | CACNA1HUSP2CYP3A4SMN1; SMN2 | |
| SCHEMBL8202683 | 0.81 | CACNA1H (0.72) | CACNA1HUSP2CYP3A4SMN1; SMN2 | |
| SCHEMBL8214075 | 0.80 | CACNA1H (0.73) | CACNA1H | |
| SCHEMBL14263416 | 0.80 | CACNA1H (0.70) | CACNA1H | |
| SCHEMBL8210029 | 0.79 | CACNA1H (0.84) | CACNA1HUSP2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | CACNA1H 2929/4885USP2 2773/4885CYP3A4 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.